HCW Biologics Inc. Received NASDAQ Staff Determination Letter
23 déc. 2024 08h10 HE
|
HCW Biologics, Inc
Mandatory press release to disclose receipt of Nasdaq Staff Determination Letter.
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
18 nov. 2024 21h27 HE
|
HCW Biologics, Inc
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
18 nov. 2024 07h00 HE
|
HCW Biologics, Inc
HCW Biologics signed license agreement with WY Biotech
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
14 nov. 2024 16h40 HE
|
HCW Biologics, Inc
Press release for Q3 2024 business highlights and financial results
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
23 août 2024 16h30 HE
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
14 août 2024 16h35 HE
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
15 mai 2024 16h39 HE
|
HCW Biologics, Inc
Earning release for Q1 2024
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
01 avr. 2024 16h10 HE
|
HCW Biologics, Inc
Q4 and Year End Earnings Release and Business Highlights
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
14 nov. 2023 07h00 HE
|
HCW Biologics, Inc
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
08 nov. 2023 07h30 HE
|
HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.